-

Allurion to Participate in Cowen’s 44th Annual Health Care Conference

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in the 44th Annual Cowen Health Care Conference, taking place on March 4 – March 6, 2024 at the Marriott Copley Place in Boston, Massachusetts. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present on Tuesday, March 5, 2024 at 9:50 a.m. Eastern Time. Management will also participate in 1x1 meetings.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan, whether it is gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Contacts

Global Media
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com

Investors
Hannah Lindberg
hlindberg@allurion.com

Industry:

Allurion Technologies, Inc.

NYSE:ALUR
Release Summary
Allurion to Participate in Cowen’s 44th Annual Health Care Conference
Release Versions
English

Contacts

Global Media
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com

Investors
Hannah Lindberg
hlindberg@allurion.com

More News From Allurion Technologies, Inc.

Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,240,000 shares of the Company’s common stock at a price of $6.00 per share in a registered direct offering priced at-the-market under NYSE rules. In addition, in a concurrent private placement, the Compan...

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition. Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.1 In contrast, in previous...

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) dated January 15, 2025 for U.S. Patent No. 12,209,677 titled “Binary Fluid Control Valve System”. This patent covers additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology and the introduction of in...
Back to Newsroom